Dalrada Technology Group Deal Termination with IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC
Dalrada Technology Group's subsidiary, Genefic, Inc., has terminated its financing relationship with IBS Equity Fund III and IBS Private Credit Fund IV, which included a $20 million standby letter of credit facility and a $5 million credit facility. Although no funding was ever received under these agreements, IBS has asserted events of default and is demanding early termination fees and the acceleration of obligations, which the company disputes.
- Counterparty
- IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC